Jeffrey Erickson

Vice President, Business Development

Jeffrey Erickson is a life sciences executive with more than 20 years of business development, investor relations, and strategic planning experience leading numerous deals, M&A transactions and R&D collaborations. He joined Triumvira in June 2023 as Vice President of Business Development.

Prior to joining Triumvira, Mr. Erickson was Senior Director of Corporate Development at PhaseBio Pharmaceuticals, where he structured and negotiated terms for licensing and development deals and helped support the company’s commercial planning and financing activities. Before that, Mr. Erickson worked as an analyst at Reneo Capital Management, a healthcare investment fund, and held roles of increasing responsibility at Orexigen Therapeutics, Arena Pharmaceuticals, Amgen, and Amylin Pharmaceuticals. Additionally, Mr. Erickson worked on the sequencing of the human genome at the Whitehead Institute/MIT Center for Genome Research (Broad Institute). Mr. Erickson earned a B.A. in Biochemistry from the University of Pennsylvania.